Oria Bioscience Fuels Innovation: Secures $2.7M Pre-Seed Investment to Revolutionize Global Organelles Distribution

Oria Bioscience is thrilled to announce the successful acquisition of €2,700,000 in new funding—a milestone that underscores our commitment to revolutionizing biotherapeutics with groundbreaking organelle technology. As a pioneering French TechBio company, Oria Bioscience leverages state-of-the-art microfluidics technology to generate high-quality, intact living organelles, including lysosomes, mitochondria, and endoplasmic reticulum, all meticulously enveloped by their therapeutic membrane targets. This transformative approach not only ensures compatibility with high-throughput screening campaigns and drug development efforts but also provides a paradigm shift in efficacy, significantly reducing attrition rates during clinical phases. The new capital infusion will be strategically deployed to upscale our production capabilities, further refine our microfluidics processes, and expand our distribution network to reach pharmaceutical laboratories and contract research organizations (CROs) worldwide. With over 50 years of combined expertise in organelle biology and microfluidic systems, our dedicated team is poised to drive innovation by making organelles as accessible as cells, fundamentally changing the landscape of drug discovery and development. The infusion of funds will also empower us to intensify our research and development agenda, accelerate Hit-to-Lead and Lead Optimization phases, and contribute to a more sustainable drug production ecosystem marked by a reduced carbon footprint. As we embark on this next chapter of growth, Oria Bioscience remains resolutely committed to supporting researchers and innovators with high-caliber biological tools that not only catalyze therapeutic breakthroughs but also herald a new era of precision medicine for global health sectors.